Benesch represented Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, during its Series D round of investing lead by Lyfe Capital which raised over $19 million in financing.
Funds raised will be used to expand commercialization of IsoPSA—the company’s first diagnostic test, designed to enhance early detection of prostate cancer—as well as to expand internal infrastructure and operations to support platform development for other tests, including breast and lung cancer.
The Benesch team included Sean Peppard and Ryan Williams.